Figure 6

Experimental validation of splicing patterns discriminating two subtypes of acute myeloid leukemia. Validation of splice variants for genes MAPK15 and PLXNB1 detected in AML patients and in mononuclear cells of healthy controls. (A) Table with the output results provided by ESLiMc method showing the exons most significantly changed in genes MAPK15 and PLXNB1. (B) Scaled pictures presenting the architecture of MAPK15 and PLXNB1 gene loci including all exons and introns. Red boxes show the coding exons; white boxes the untranslated regions (UTR); pink shadow boxes mark the exons which undergo splicing (ENSE00001663392 for MAPK15 and ENSE0000108091 for PLXNB1). (C) Validation by RT-PCR performed with RNA samples from 12 AML patients (6 CBF-AML and 6 CK-AML) and with RNA from mononuclear cells of 6 healthy probands. The splice isoforms differentially expressed between the two AML subgroups are marked with red arrows. The splice isoforms differentially expressed between AML subgroups and the mononuclear blood fraction from healthy donors are marked with green arrows. NTC is for “no template control”. Beta-actin was used as loading control. The architecture of the specific exon/intron region from genes MAPK15 and PLXNB1 that show changes is presented aside.